GSK gets cancer immunotherapeutics from MD Anderson
The University of Texas’ MD Anderson Cancer Center has licensed GlaxoSmithKline PLC exclusive global rights to develop and sell OX40-activating antibodies for cancer. NOTE: One of the antibody programs is known as GSK3174998.
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com